Harrow Health (HROW) Announces Leading Peer-Reviewed Journal Publishes Clinical Study on ImprimisRx’s Combination Prescription Eyedrops

ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), is pleased to announce the findings from a randomized contralateral eye study comparing patient outcomes and preferences for a combination therapy with individual eye drop medications after ocular surgery. The prospective study was conducted at a single site where patients underwent cataract surgery with both eyes and each eye was randomly selected for the test and control group. Subjects were evaluated at day 1, 15 and 30 measuring visual acuities, refraction, intraocular pressure, macular thickness, patient pain and overall patient satisfaction. According to the study, the ImprimisRx combination drop showed similar health outcomes to multiple separately dosed drops, and that the combination drop was unanimously preferred by patients as it was easier to manage.

The results of the study were recently published in Clinical Ophthalmology, Volume 14, 2020, a peer-reviewed journal focused on the clinical advancements in ophthalmology. The study followed 33 patients who underwent cataract surgery and received the combination drop (prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac sodium 0.075%) in one randomly selected eye, while the other eye received the same individual eye drop medications post-surgery.

It was noted by the investigator, “Enrollment for this study was relatively slow, as it was difficult to find eligible patients willing to use the three different drops instead of the combination drop; the latter is the standard of care in our clinic.”

John Saharek, President of ImprimisRx, commented, “Post ocular surgery, patients are usually required to instill multiple topical drops to prevent infection, inflammation, and pain, often with a different bottle used for each drop. For some patients this can be confusing and/or can be burdensome, which could lead to non-compliance and suboptimal health outcomes. ImprimisRx formulations such as LessDrops® provide the unique ability to combine these individual ingredients into one bottle.”

The full study can be found on the Dovepress website or by clicking here.

You May Also Be Interested In

• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• BioXcel Therapeutics (BTAI) Announces Plan for Evaluating BXCL501
• BeiGene (BGNE) Receives EU Approval for Tislelizumab